Click a link below to view the mailing archive as if it had been sent to you.
| 2022-10-31 12:15 | | Thermo Fisher Scientific buys European diagnostics firm for $2.6B and more... |
| 2022-10-31 00:15 | | AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now and more... |
| 2022-10-28 12:15 | | Sanofi reveals setback for cancer drug acquired in Synthorx buyout and more... |
| 2022-10-28 00:15 | | An unusual alliance opens a gene and cell therapy hub outside Boston and more... |
| 2022-10-27 12:15 | | Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says and more... |
| 2022-10-27 00:15 | | J&J nabs FDA okay for BCMA bispecific Tecvayli and more... |
| 2022-10-26 12:15 | | Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval and more... |
| 2022-10-26 00:15 | | How pharma companies can leverage asynchronous telemedicine and more... |
| 2022-10-25 12:15 | | Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates and more... |
| 2022-10-25 00:15 | | Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline and more... |
| 2022-10-24 12:15 | | Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug and more... |
| 2022-10-24 00:15 | | Just announced: upcoming late-stage clinical trials in weight loss and diabetes and more... |
| 2022-10-21 12:15 | | FDA finalizes multiple endpoints guidance and more... |
| 2022-10-21 00:15 | | Takeda sues Apotex over prospective generic versions of its top leukemia drug and more... |
| 2022-10-20 12:15 | | Pfizer CEO Bourla says company ready to execute in a 'pivotal' 2023: report and more... |
| 2022-10-20 00:15 | | FDA authorizes Novavax’s Covid-19 booster, a first for a protein-based vaccine and more... |
| 2022-10-19 12:15 | | Gilead touts Veklury resilience against mutated coronavirus, plots phase 3 for new COVID oral antiviral and more... |
| 2022-10-19 00:15 | | Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets and more... |
| 2022-10-18 12:15 | | Eli Lilly to buy precision medicine company Akouos for $487M and more... |
| 2022-10-18 00:15 | | Milestone's Nasal Spray for PSVT Hits the Mark in Phase III and more... |
| 2022-10-17 12:15 | | Biogen's ALS ambitions on pause as FDA delays approval decision by 3 months and more... |
| 2022-10-17 00:15 | | Covalent drugs take the stage — again — in Atlas Venture’s latest startup and more... |
| 2022-10-14 12:15 | | Novartis' blockbuster Gilenya exposed to generics in short term amid Supreme Court appeal and more... |
| 2022-10-14 00:15 | | Ionis to build new manufacturing site in Southern California, doubling the size of its current site and more... |
| 2022-10-13 12:15 | | GSK hits back in high-stakes RSV vaccine game, posting phase 3 data that suggest it has edge on Pfizer and more... |
| 2022-10-13 00:15 | | Novartis' Zolgensma Under Fire Again as Nature Retracts 2010 Paper and more... |
| 2022-10-12 12:15 | | 4 Biotech Stocks With Huge Incoming Catalysts and more... |
| 2022-10-12 00:15 | | TauRx’s HMTM could be the first anti-tau disease-modifying drug for Alzheimer’s and more... |
| 2022-10-11 12:15 | | AstraZeneca’s Covid-19 nasal-spray version fails in trial and more... |
| 2022-10-11 00:15 | | Global clinical trials activity decreases 12.2% in Q3 2022 over 4Q average and more... |
| 2022-10-10 12:15 | | Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy and more... |
| 2022-10-10 00:15 | | Merck Covid antiviral pill did not cut hospitalization risk, study finds and more... |
| 2022-10-07 12:15 | | R&D acceleration: Amgen opens its second largest research site, with lab and office space for 650 staff and more... |
| 2022-10-07 00:15 | | Genetesis rakes in $17.5M as its heart disease test prepares for market entry and more... |
| 2022-10-06 12:15 | | Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy and more... |
| 2022-10-06 00:15 | | NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins and more... |
| 2022-10-05 12:15 | | GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement and more... |
| 2022-10-05 00:15 | | New model says Type 1 diabetes cases worldwide could double by 2040 and more... |
| 2022-10-04 12:15 | | Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim and more... |
| 2022-10-04 00:15 | | Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst and more... |
| 2022-10-03 12:15 | | AstraZeneca pays 666% premium to buy genomic medicine biotech and more... |
| 2022-10-03 00:15 | | New pediatric data shoot Rocket's gene therapy toward phase 2, leaving behind FDA concerns and more... |
| 2022-10-01 00:15 | | Teva settles price-fixing claims with Georgia for a 'modest' $3.3M and more... |
